20 medicines, injections manufactured in Himachal fail quality tests
In a concerning development, 20 medicines and injections manufactured in Himachal Pradesh have failed to meet quality standards. Most of the failed products are from pharmaceutical companies located in the Baddi-Barotiwala-Nalagarh (BBN) industrial area.
Additionally, a sample of a natural protein shampoo also failed to pass the quality tests.
Among the failed products are several critical medicines, including an injection used to reduce fungal infections in the lungs and control dehydration. These products did not meet the standards set by the Central Drugs Standard Control Organisation (CDSCO).
The list of failed medicines includes Fungobi capsules and pantoprazole from Bonsai Pharma, Kishanpura; compound sodium lactate injection from Higgs Healthcare, Bhattolikalan, Baddi; Itraconazole capsules from Ultra Drugs Private Katha, and carbamazepine-e extended release tablets from JP Industries, Bhud.
Also Read : https://thenewzradar.com/in-himachal-its-bjp-vs-bjp-over-building-indoor-stadium-in-mandi-as-party-leader-takes-on-mla-anil-sharma/
Other products that did not meet the standards include calcium carbonate b6 (Comed-CM) from Broad Injectables, Tahliwal, Una; azithromycin and compound sodium lactate injection from Emsa Pharmaceuticals, Paonta; and ofloxacin-ornidazole tablets from Unigro Pharmaceuticals, Katha, Baddi.
Further, cinetavit capsules from Lifevision Healthcare, Jharmajri; pantoprazole and rabeprazole from Martin & Brown Biosciences, Baddi; Jalomoxi CV from Micro Formulation, Chambaghat; Stopmust Injection from Ilvis Care, Baddi, and pantoprazole from Arge Healthcare, Parwanoo, were also found to be substandard.
Ultra Drugs Mankpur’s cough syrup, Bioglip-1 from IBN Herbals, Baddi, ciprofloxacin hydrochloride from HPSIDC, and natural protein shampoo from Himalayan Wellness, Baddi, also failed the quality tests.
State Drug Controller Manish Kapoor stated that show-cause notices had been issued to the pharmaceutical companies responsible for these products. The failed products pose serious concerns for public health and strict actions are likely to follow to ensure compliance with regulatory standards.
